Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Breast Cancer, Metastatic • Breast Cancer, Non-metastatic
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
Answer from: Medical Oncologist at Community Practice
That's an interesting question. The contralateral axilla would be considered metastatic, so there would be approval to use fulvestrant/elacestrant in that setting. It would be interesting to know when the patient finished their prior adjuva...
Sign in or Register to read more